Fresenius Medical Care
Fresenius Medical Care Appoints Shervin J. Korangy Chief Executive Officer
Fresenius Medical Care announced a leadership change on October 7, 2026. Fresenius Medical Care appointed Shervin J. Korangy, former BVI Medical CEO, to succeed Helen Giza as CEO and lead its next phase of strategic development and long-term profitable growth.
What changed
Shervin J. Korangy was named Chief Executive Officer and Chair of the Management Board. Helen Giza has served as CEO and Chair of the Management Board for four years, following three years as CFO, and Korangy succeeds her effective October 12, 2026.
- Leader: Shervin J. Korangy
- Role: Chief Executive Officer and Chair of the Management Board
- Effective: October 12, 2026
- Announcement date: October 7, 2026
Leadership background
Korangy was President and Chief Executive Officer of BVI Medical from 2017 to 2026, stepped down in January 2026, and then served as a senior advisor to BVI and TPG Capital. Earlier he was a senior executive at Novartis and spent over 14 years at Blackstone, most recently as a Managing Director. He is a co-founder of Sight Sciences and has been a member of the Fresenius Medical Care Supervisory Board since 2023, a position he resigned from in light of his appointment as CEO.
The mandate
Fresenius Medical Care said it will focus on accelerating long-term profitable growth, advancing innovation, strengthening its market leadership and creating sustainable value for patients, customers and shareholders as Korangy takes over.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Fresenius Medical Care leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started